NASDAQ:MBIORecognized as an innovator in the chimeric antigen receptor (CAR) engineered T cell (CAR-T) space, Mustang Bio (NASDAQ:MBIO) has focused its efforts on immuno-oncology indications since its inception in 2015. The company targets both liquid and solid tumors using CAR-T and has built a facility to supply manufactured cell...
By Brian Marckx, CFANASDAQ:MNKDREAD THE FULL MNKD RESEARCH REPORTZacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. See above for free access to our 36-page report on the company.SNAPSHOTMannKind Corporation (NASDAQ:MNKD) was founded in the early 2000’s...
OTC:ALPEAlpha-En Corp (OTC:ALPE) is a technology development company focused on enabling next-generation battery technologies through the development of processes that target significant performance advances for lithium batteries, specifically the production of very high purity lithium metal through a patent-pending process. This production process, which is currently in the developmental...
By Steven Ralston, CFAOTC:GRWGREAD THE FULL GRWG RESEARCH REPORTEXECUTIVE SUMMARY OF RECENT EVENTSIn the third quarter of 2018, sales increased 109% to approximately $8.41 million versus $4.03 million during the comparable quarter in 2017. Working capital has improved 315% to $23,139,534 due to a $10 million private placement of...
By John Vandermosten, CFANASDAQ:AZRXREAD THE FULL AZRX RESEARCH REPORTOn November 9th, AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its third quarter 10-Q with the SEC for the three month period ending September 30, 2018. Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data,...
By John Vandermosten, CFANASDAQ:PHIOREAD THE FULL PHIO RESEARCH REPORTPHIO Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. The company disclosed its quarterly performance and highighted the financial and scientific events that occurred during the period. In August, topline results from the...
By John Vandermosten, CFATSE:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORTThird Quarter 2018 ResultsProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) has experienced a busy quarter since our previous report providing presentations and press releases addressing the:‣ safety profile of PMN310 with respect to BAN2401 and aducanumab;‣ the importance of selectivity against...
By Brian Marckx, CFANASDAQ:EYEG | NYSE:AGNREAD THE FULL EYEG RESEARCH REPORTQ3 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) announced Q3 financial results and provided a business update. In terms of the financials, milestone from the EGP-437 development agreement with Bausch Health Companies (BHC, formerly Valeant Pharmaceuticals) in the amount $315k was...
By Brian Marckx, CFANASDAQ:CEMIREAD THE FULL CEMI RESEARCH REPORTQ3 2018: Record YTD revenue, margins take a hit but should begin to rebound…Chembio (NASDAQ:CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made it three-for-three with us substantially underestimating product and total revenue every quarter so...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdatePart 1 of Phase 2b Dose-Ranging, Efficacy Study Successfully CompletedOn November 27, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced that it has successfully completed the first part of the Phase 2b dose-ranging, efficacy study of ATB-346. The first part of the...